Le Lézard
Classified in: Health, Science and technology, Business
Subjects: LIC, VEN

Novo Holdings Portfolio Company F2G enters strategic collaboration with Shionogi to commercialise its new antifungal agent Olorofim in Europe and Asia


COPENHAGEN, Denmark, May 16, 2022 /PRNewswire/ -- Novo Holdings A/S, a leading international life sciences investor, today announces that its portfolio company F2G Ltd. (F2G) has entered into a strategic collaboration with Shionogi & Co., Ltd. (Shionogi) to develop and commercialise its antifungal agent olorofim for invasive fungal infections, in Europe and Asia.

F2G is a UK, US and Austria based biotech company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. Novo Ventures, the venture capital team at Novo Holdings, has led and participated in a series of financings since 2016. Naveed Siddiqi, Senior Partner at Novo Holdings, serves as a Board Member of F2G and Eric Snyder, Partner at Novo Holdings, as Board Observer.

Olorofim is a novel oral antifungal therapy developed by F2G to treat invasive aspergillosis (IA) and other rare mold infections. Olorofim works through a unique mechanism of action, different from all existing classes of antifungals, exerting fungicidal activity through inhibition of the pyrimidine synthesis pathway. Olorofim represents the first truly novel antifungal class developed in the past 20 years and is the only antifungal medication to be awarded a Breakthrough Therapy Designation (BTD) for multiple indications by the US Food & Drug Administration (FDA).

The world market for antifungal agents is currently worth in excess of US$6 billion with consistent annual growth driven by year-on-year increases in the susceptible immune compromised patient population. Increases in cancer, organ transplants and use of potent drugs, including broad spectrum antibiotics has led to significant increases in fungal infections. Fungi are now recognised as a major issue in several respiratory conditions, being responsible for exacerbations of symptoms in asthma, COPD and bronchiectasis patients. This is likely to increase the use of antifungal drugs over the coming years. F2G believes that its novel agent, olorofim, and subsequent agents, will address some of the many challenges which face the treating physician and the patient with invasive fungal infections.

Olorofim is currently in a Phase 2b open-label study and Phase 3 randomized study ("OASIS").

Naveed Siddiqi, Board Director of F2G and Senior Partner, Novo Holdings, said: "Globally there is a high unmet medical need for novel antifungal therapies that are active against resistant and refractory infections and also against pathogenic fungal species which have been difficult to successfully treat historically. F2G is developing a completely new class of antifungal agents called the orotomides. The strategic collaboration with Shionogi is an exciting development for the Company as it offers the prospect of olorofim, once approved, to reach even more patients around the world. This is Novo Ventures' second anti-infective investment in 2022 that has attracted interest from partners in the pharmaceutical industry."

Francesco Maria Lavino, Chief Executive Officer of F2G, said: "This collaboration will enable us to progress the development of olorofim with a regional partner. Shionogi has a proven track record in both global drug development and business development and we look forward to working closely together while we now concentrate our efforts on the development and commercialisation of olorofim for the US market."

Since January 2020, Novo Ventures has helped deploy over US$1.1 billion in life science investments. The team consists of highly experienced investment professionals who operate from Copenhagen, Boston, London and San Francisco. The team advises on investments in early-stage startups through later stage crossover financings. On the public side, the team helps catalyse IPOs and follow-on financings as well as participation in the open market. 

About Novo Holdings A/S

Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation's assets.

Novo Holdings is recognised as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.

Further information : https://www.novoholdings.dk/investments/ventures/

About F2G

F2G is a biotech company with operations in the UK, US, and Austria focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides which selectively target a key enzyme in the de novo pyrimidine biosynthesis pathway. This is a completely different mechanism from that of the currently marketed antifungal agents and gives the orotomides fungicidal activity against a broad range of rare and resistant fungal mold infections. For more details, please visit the F2G web site.

 

SOURCE Novo


These press releases may also interest you

at 12:30
New data presented in two separate oral presentations at the European Association for the Study of the Liver's International Liver Congress 2022 (EASL ILC 2022)Following 90 days of dosing, ATI-2173, in combination with tenofovir disoproxil fumarate...

at 11:54
With its ruling today, the U.S. Supreme Court has overturned Roe v. Wade, dismantling the constitutional right to abortion that has stood for nearly 50 years. Roe is overturned at a time when 26 states are poised to ban abortion which will leave 36...

at 11:22
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Apyx Medical Corporation between May 12, 2021 and March 11, 2022, both dates inclusive (the "Class Period"), of the important August 5, 2022 lead...

at 09:05
Ionis Pharmaceuticals, Inc. , today...

at 04:05
AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients 50% (16 out of 32) of patients maintained HBsAg levels below 100 IU/mL 24 weeks after their last AB-729 dose In the first five patients...

at 00:35
Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the South African Health Products Regulatory Authority (SAHPRA) granted conditional registration to SINOVAC CoronaVac®...



News published on 16 may 2022 at 03:09 and distributed by: